Anogen-Yes Biotech

10/15/2025

🧠 A recent Nature Reviews Drug Discovery article outlines a bold vision for the future of AD therapies — expanding beyond amyloid-β to target Tau, ApoE, and α-synuclein, and harnessing next-gen tools like protein degraders, RNA drugs, and brain-penetrant antibodies.

Collaboration and innovation will drive the next wave of breakthroughs.

🔗 Read more: https://pubmed.ncbi.nlm.nih.gov/40770764/

After decades of disappointment, three disease-modifying therapies for Alzheimer's disease (AD) have been approved since 2021. Burgeoning clinical data on these amyloid β-protein (Aβ) targeting drugs validate the amyloid cascade hypothesis as a molecular roadmap for the development of yet more eff...

10/08/2025

A review in Neural Regeneration Research highlights how targeting tau protein—a key driver of neurodegeneration—may unlock new, earlier, and safer treatment strategies for Alzheimer’s disease.

Read the full article here: https://pubmed.ncbi.nlm.nih.gov/38051891/

Alzheimer's disease is the most prevalent neurodegenerative disease affecting older adults. Primary features of Alzheimer's disease include extracellular aggregation of amyloid-β plaques and the accumulation of neurofibrillary tangles, formed by tau protein, in the cells. While there are amyloid-β...

10/01/2025

🎉 Anogen W.X. LifeAntibody Solution Ltd. is honored to be an official sponsor of the 5th CBA Canada Annual Conference!

On September 27, 2025, we proudly joined this successful event in Toronto. By supporting this conference, we aim to collaborate with global experts, scholars, and industry partners to explore the limitless possibilities of biotechnology.

As a company dedicated to biotech innovation, Anogen is committed to advancing life sciences through cutting-edge research and solutions. We firmly believe that collaboration and knowledge exchange are key drivers of progress in our industry.

🌐 Learn more: www.anogen.ca

09/22/2025

A Frontiers in Pharmacology analysis of FAERS data (2004–2024) highlights potential thrombotic risks linked to TNF-α blockers. The research found safety signals across patient groups, stressing the need for careful monitoring of clotting events in real-world use.

🔗 Read on PubMed: https://pubmed.ncbi.nlm.nih.gov/40351429/

This study suggests that TNF - α blockers are associated with various adverse events of thrombosis, with different risks in different patient groups and treatment stages. Clinical doctors should assess individual thrombosis risk and closely monitor coagulation related indicators when using TNF - α...

09/17/2025

A recent review in Neurodegenerative Diseases discusses active immunization (vaccination) against amyloid-beta as a potential therapy for Alzheimer’s disease. Unlike current drugs that mainly relieve symptoms, vaccines may directly target and reduce disease-driving amyloid plaques — offering the possibility of longer-lasting benefits with fewer clinic visits.

The article highlights both progress and challenges from past and ongoing trials, underscoring the promise of this innovative approach.

🔗 Read more on PubMed: https://pubmed.ncbi.nlm.nih.gov/40349697/

This review highlights the potential for vaccination development to treat AD, including its efficacy, associated complications, and limitations. Much progress has been made over the past 2 decades, but challenges remain. Immunization is a promising avenue for treating or preventing symptomatic AD, o...

09/10/2025

IL-17 inhibitors are a groundbreaking class of biologics that specifically block the pro-inflammatory cytokine IL-17A. They offer significant relief in conditions like moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis by targeting the root cause of inflammation, without dampening the entire immune system. It’s a powerful shift toward precision immunotherapy.

Read the full article: https://www.drugs.com/medical-answers/what-il-17-inhibitors-how-work-3580511/

Official answer: IL-17 inhibitors are biologic drugs that block interleukin-17, a key protein that fuels inflammation in autoimmune...

09/03/2025

A study published in PLoS ONE (Jiang et al., 2014) utilized the Anogen Human TNF-α ELISA Kit (EL10019) to investigate a novel tumor-targeted recombinant mutated TNF-α (RGD-rmhTNFα).

Key findings:
* RGD-rmhTNFα significantly enhanced the antitumor efficacy of doxorubicin.
* Mechanism: by increasing tumor vessel permeability, leading to improved drug delivery into tumor tissue.
* Using Anogen’s ELISA kit, researchers quantified TNF-α distribution in serum and tumor tissues of xenograft mouse models.

✨ This work highlights how precise cytokine quantification supports the development of innovative cancer therapies.
👉 Read the article: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087036

08/27/2025

We are excited to introduce our Multiplex Human Cytokine ELISA Kit (EM10004) — designed to advance CAR-T and immunology applications.

✨ Key Features:

Simultaneous detection of 8 cytokines (IL-1β, IL-6, IL-8, IL-10, IL-15, GM-CSF, IFN-γ, MCP-1)
Validated detection ranges ensuring high sensitivity and reproducibility
Fast & reliable: 3.5-hour solid phase immunoassay with no cross-reactivity
Suitable for serum, plasma, and cell culture supernatants

📊 Representative standard curves demonstrate wide dynamic range and excellent assay sensitivity.

👉 Learn more at https://www.anogen.net/multiplex-human-cytokine-elisa-kit-car-t.html

-T

08/20/2025

At AAIC 2025, Merck presented preclinical data for MK‑2214, a novel anti‑tau antibody targeting the pS413 epitope, highly associated with Alzheimer’s pathology.

Precision targeting: Selectively binds pathological tau species.

Robust preclinical efficacy: Reduces tau seeding in iPSC neurons and animal models.

Optimized pharmacokinetics: Extended half-life supports less frequent dosing, with the potential for convenient subcutaneous administration.

Clinical momentum: Advancing through Phase II trials for early cognitive impairment.

This represents an exciting shift toward disease-modifying strategies that address tau spread, offering fresh hope in Alzheimer’s research.

Read the full article here: https://www.neurologylive.com/view/aaic-2025-preclinical-results-anti-tau-antibody-mk-2214-ad-jonathan-sugam

The principal scientist of neuroscience discovery at Merck presented preclinical data at AAIC 2025 supporting the development of MK-2214, an anti-tau antibody designed to slow or prevent the progression of AD. [WATCH TIME: 5 minutes]

08/13/2025

🎉 Celebrating 36 Years of Scientific Excellence!

2025 marks Anogen’s 36th anniversary, a proud milestone in our mission to advance global research in immunology, cancer, neuroscience, and infectious diseases.

For over three decades, we’ve delivered high, quality antibodies, ELISA kits, and custom solutions to scientists, clinicians, and diagnostic developers worldwide.

💡 Our commitment to innovation and collaboration has fueled countless discoveries, and we’re just getting started.

🙏 A heartfelt thank you to our customers, partners, and team members for making this journey possible. Here’s to the future of science!

08/06/2025

Tiziana Life Sciences’ nasal Foralumab, a fully human anti-CD3 antibody, has received FDA clearance for a Phase II trial in Alzheimer’s patients.

Why it matters:

🐭 In preclinical studies, intranasal anti-CD3 improved cognition in 3xTg mouse models — without reducing amyloid beta.

🧬 It works by reducing neuroinflammation, switching microglia to a healthier state, and enhancing synaptic and metabolic function.

🧘‍♂️ It also boosts regulatory T cells (Tregs), which enter the brain and calm inflammation.

This opens the door to non-invasive, amyloid-independent immunotherapy for AD — potentially complementary to existing anti-amyloid treatments.

🔗 Learn more: https://www.tizianalifesciences.com/fda-clears-foralumab-nasal-spray-for-expanded-use-in-alzheimers

Dosing of first patient is expected to happen this month by Margarida Maia, PhD | July 11, 2024 Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s di...

07/30/2025

A review in Nature Reviews Neurology spotlights intranasal Foralumab—Tiziana’s lead biologic therapy—as a novel solution across neurodegenerative diseases including MS, Alzheimer’s, ALS, and Parkinson’s. By calming overactive microglia and tuning immune cell interaction, Foralumab may offer safe, non-invasive relief where options are limited. Insights from Dr. Howard Weiner and CEO Ivor Elrifi underscore Tiziana’s commitment to transformative neuro-immunology.
Read how one nasal therapy could change the game: full review article available now.

Read the full article: https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-life-sciences-announces-review-article-published-nature